Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA clears Abbott's dual-energy ablation catheter for complex AFib

FDA clears Abbott's dual-energy ablation catheter for complex AFib

New Capabilities

TactiFlex Duo combines pulsed field and radiofrequency energy in a single device.

4 days ago: FDA approves TactiFlex Duo dual-energy catheter

Overview

Updated 2 days ago

The Food and Drug Administration cleared Abbott's TactiFlex Duo, the first U.S. ablation catheter to combine pulsed field and radiofrequency energy. The device is designed for complex atrial fibrillation, a condition affecting about 10.5 million Americans.

The approval rests on 12-month data from the FlexPulse study. 74.6% of patients stayed free of arrhythmias, and 92.6% had no recurrence under standard monitoring. Abbott says U.S. commercial cases will begin within weeks.

Why it matters

It gives doctors a single tool to switch energy types mid-procedure, which could reduce repeat ablations for millions of AFib patients.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

74.6%
Freedom from arrhythmias at 12 months
Primary effectiveness endpoint of the FlexPulse IDE study.
92.6%
No recurrence of AFib on standard monitoring
Secondary outcome measure from the same study.
2
Energy modalities in one catheter
Combines pulsed field ablation and radiofrequency in a single device.
10.5M
U.S. patients with abnormal heart rhythms
Estimated population living with AFib or related rhythm disorders.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Organizations Involved

Abbott
Abbott
Medical device and healthcare company
Expanding U.S. and global ablation portfolio

Global healthcare leader with a growing electrophysiology division.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Cleared TactiFlex Duo for commercial use

Federal agency responsible for protecting public health by regulating medical devices.

Timeline

May 2023 September 2026

6 events Latest: 4 days ago
Tap a bar to jump to that date

  1. FDA approves TactiFlex Duo dual-energy catheter

    Latest Regulatory Approval

    First U.S. approval for a catheter combining pulsed field and radiofrequency energy.

  2. TactiFlex Duo receives European CE mark

    Regulatory Approval

    Dual-energy catheter gains European approval in January.

  3. FDA approves Volt PFA system in the U.S.

    Regulatory Approval

    Volt becomes Abbott's first U.S.-approved pulsed field ablation system.

  4. FDA grants Breakthrough Device Designation to TactiFlex Duo

    Regulatory

    Designation for treating ventricular tachycardia, which would extend the catheter's use beyond AFib.

  5. Volt PFA receives European CE mark

    Regulatory Approval

    Abbott's pulsed field ablation system gains approval in Europe.

  6. FDA clears original TactiFlex catheter

    Regulatory Approval

    Cleared the RF-only version of TactiFlex for cardiac ablation.

Scenarios

1

TactiFlex Duo becomes standard for complex AFib cases

Likely Resolves by Mar 1, 2028

Discussed by: Industry analysts at GlobalData and leading electrophysiologists

If reimbursement holds and early adopters report success, the Duo could become the default choice for complex anatomies, displacing single-energy systems. Adoption within 18 months will signal this path.

2

Rivals close the gap with their own dual-energy catheters

Possible Resolves by End of 2028

Discussed by: Medical Device Network, competitive intelligence reports

Boston Scientific, Medtronic, and J&J all have PFA systems. With Abbott's dual-energy lead, they will accelerate internal programs to combine PFA with RF or other modalities. A competing FDA clearance within two years is plausible.

3

Reimbursement limits slow adoption of dual-energy technology

Unlikely Resolves by Q2 2027

Discussed by: CMS policy watchers and hospital purchasing groups

If Medicare sets separate reimbursement codes for PFA and RF, hospitals may stick with single-energy systems to minimize cost. This could keep the Duo as a niche option for the most difficult cases only.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2010

Arctic Front Cryoballoon FDA approval (2010)

Medtronic's Arctic Front cryoballoon was the first major ablation technology shift in a decade. It used frozen balloons to isolate pulmonary veins, offering an alternative to point-by-point radiofrequency ablation.

Then

Cryoballoon became a workhorse for treating paroxysmal AFib across Europe and the U.S.

Now

It established catheter ablation as a mainstream therapy, leading to the current PFA and dual-energy era.

Why this matters now

Shows how new ablation technologies move from first approval to standard of care, a pattern the TactiFlex Duo aims to follow.

November 2011

Edwards Sapien TAVR approval (2011)

The FDA approved the first transcatheter aortic valve replacement, allowing severely ill patients to avoid open-heart surgery. Edwards Lifesciences' Sapien valve was initially limited to high-risk patients.

Then

TAVR was quickly adopted, expanding to intermediate and low-risk patients within a few years.

Now

TAVR became the standard of care, transforming how heart valve disease is treated worldwide.

Why this matters now

Demonstrates how a novel technical capability in a single device can rapidly expand its approved patient population and displace older surgical approaches.

December 2023

Medtronic PulseSelect PFA approval (2023)

The FDA cleared the first pulsed field ablation catheter for atrial fibrillation, reshaping the cardiac ablation market. Medtronic's PulseSelect system delivered targeted electric fields to heart tissue without the heat or cold effects of older methods.

Then

PFA quickly became a preferred option for paroxysmal AFib due to lower complication rates.

Now

PFA adoption surged, prompting competitors like Abbott, Boston Scientific, and J&J to accelerate their own programs.

Why this matters now

Set the stage for the current competitive battlefield. Abbott's dual-energy device is the next step beyond this single-energy breakthrough.

Sources

(10)
+4
Fierce Biotech Abbott MediaRoom Medical Device Network PR Newswire Hospimedica MarketWatch DAIC Cardiovascular Business Nova Pharma News Indian Pharma Post